Navigation Links
Vaccine shown effective against chancroid

HIV plagues more than 25 million people in sub-Saharan Africa, according to the World Health Organization, and efforts to develop a vaccine against the virus have achieved limited success. But what if a vaccine against another sexually transmitted infection found widely in that region of Africa ?chancroid ?was relatively easy to develop and could reduce transmission of HIV as much as 10-fold?

That may be the case, according to researchers from the University of North Carolina at Chapel Hill's School of Medicine and N.C. State University's College of Veterinary Medicine.

Their study appears in the April issue of the journal Infection and Immunity. The lead author is Dr. Galyna Afonina, postdoctoral research associate in the UNC Center for Infectious Diseases. Senior author is Dr. Christopher Elkins, research associate professor in the departments of medicine and microbiology and immunology in UNC's School of Medicine.

Chancroid, a sexually transmitted disease that causes genital ulcers, is rare in the United States but takes hold in communities that have little or no access to health care, such as in Africa. Recent studies show that genital ulcer diseases such as chancroid can enhance HIV transmission three- to 10-fold.

"There is considerable evidence that genital ulcers are independent risk factors for the transmission of HIV, and chancroid may be the most important one," said Elkins.

Chancroid is caused by a bacterium, Haemophilus ducreyi, that normally infects only humans. Unlike most bacteria, Haemophilus species are unable to synthesize heme, the ferrous, or iron-containing, component of hemoglobin, and obtain it from host hemoglobin.

The researchers found that immunizing swine with a purified hemoglobin receptor protected the animals from a challenge infection, even after multiple attempts at infection.

Blood tests showed that the immunized pigs formed antibodies that prevented the chancroid bacteria from binding hemoglobin and, hence, obtaining the heme it needs to survive, the authors said.

In skin biopsies of the immunized animals, the researchers found no viable chancroid bacteria.

An HIV vaccine has been elusive in part because the virus constantly varies its surface molecules, making it an ever-changing target. But H. ducreyi, unlike other sexually transmitted bacteria, doesn't have such a protective mechanism.

The current study and other studies suggest that developing a chancroid vaccine would be a relatively simple task, Elkins said.

Commercial sex workers infected with chancroid form a "reservoir" of infection, Elkins said. A vaccine strategy of vaccinating female sex workers against chancroid could shut down the cycle of infection, eliminating the disease of not only sex workers but their sexual partners.

And evidence suggests that eliminating chancroid throughout Africa could help reduce the transmission of HIV.

"Diverting but a fraction of the effort on HIV potentially could rapidly lead to a chancroid vaccine. I believe it is imperative that international and U.S. agencies address this opportunity in a timely manner," Elkins said.

In addition to Afonina and Elkins, other UNC authors are postdoctoral research associate Dr. Isabelle Leduc and postdoctoral trainee Dr. Igor V Nepliouev, both of the Center for Infectious Diseases; Dr. Marcia Hobbs, research associate professor in the departments of medicine and microbiology and immunology; and Chrystina Jeter, former undergraduate research assistant in Elkin's lab.

Authors from N.C. State University's College of Veterinary Medicine are Patty Routh, research technician; Dr. Glen Almond, professor of population health and pathobiology; and Dr. Paul E. Orndorff, professor of population health and pathobiology and microbiology and immunology. Elkins said that further development of the vaccine studied is needed, including perfecting ways to pur ify large amounts of the hemoglobin receptor substance and testing it with an adjuvant approved for human use.


'"/>

Source:University of North Carolina School of Medicine


Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. New Vaccine To Be Used For First Time In Polio Outbreak Response
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... Kingdom , Jan. 8, 2016   Bruin Biometrics, ... today announced the closing of a $9 million financing. The ... the financing will be used to accelerate the commercialization of ... early-stage pressure ulcers. United Kingdom ... Mark approval. The device,s introduction has been met with enthusiasm ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC ... markets for biometric technologies and devices, identifying newer markets ... for various types of biometric devices. Includes forecast from ... Identify newer markets and explore the expansion of ... devices. Examine each type of biometric technology, determine its ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... for clean technology companies in the TSX Venture 50 TM ... listed on the TSX Venture Exchange, in each of five ... technology & life sciences, diversified industries and technology – ... return on investment, market cap growth, trading volume and analyst ...
(Date:2/8/2016)... Feb. 8, 2016  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has ... with Hercules Technology Growth Capital, Inc. and Hercules ... in financing. --> ... million of financing under the loan and security ...
(Date:2/8/2016)... , Feb. 8, 2016 Novan, Inc. today announced that ... the Board of Directors of Novan. In addition, Robert Keegan ... North Carolina . --> ... announced that it received a total of $32.8 million of net ... its private investor network originating throughout the Research Triangle area of ...
(Date:2/8/2016)... , Feb. 8, 2016  BioElectronics Corporation (OTC ... devices, announced today that it is responding to ... from the Securities and Exchange Commission posted on ... , Chairman of the Board of BioElectronics Corporation ... Business Administration at The Fuqua School of Business, ...
Breaking Biology Technology: